Veracyte, Inc. Stock price

Equities

VCYT

US92337F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
21.58 USD +2.27% Intraday chart for Veracyte, Inc. -4.77% -21.56%
Sales 2024 * 398M Sales 2025 * 443M Capitalization 1.58B
Net income 2024 * -17M Net income 2025 * -3M EV / Sales 2024 * 3.42 x
Net cash position 2024 * 220M Net cash position 2025 * 266M EV / Sales 2025 * 2.97 x
P/E ratio 2024 *
-89.9 x
P/E ratio 2025 *
-518 x
Employees 815
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.57%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.27%
1 week-5.02%
Current month-8.37%
1 month-12.77%
3 months-23.39%
6 months-13.85%
Current year-21.56%
More quotes
1 week
20.98
Extreme 20.98
22.80
1 month
20.98
Extreme 20.98
25.07
Current year
20.98
Extreme 20.98
29.16
1 year
19.52
Extreme 19.52
30.52
3 years
14.85
Extreme 14.85
59.84
5 years
13.90
Extreme 13.9
86.03
10 years
4.21
Extreme 4.21
86.03
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 21-05-31
Director of Finance/CFO 46 21-07-18
Chief Tech/Sci/R&D Officer - 22-06-30
Members of the board TitleAgeSince
Director/Board Member 67 08-01-31
Chairman 69 15-01-11
Director/Board Member 74 12-11-30
More insiders
Date Price Change Volume
24-03-18 21.58 +2.27% 961,770
24-03-15 21.1 -0.75% 2,608,045
24-03-14 21.26 -3.67% 650,425
24-03-13 22.07 -1.12% 674,195
24-03-12 22.32 -1.50% 695,816

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Veracyte, Inc. is a global diagnostics company. The Company is engaged in the development and commercialization of diagnostic products and biopharmaceutical services. It offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. It also offers an Immunogram, which provides an understanding of the tumor immune microenvironment by integrating data from a variety of genomic, transcriptomic, and proteomic platforms. Its tests in the United States are serviced through its own CLIA-certified laboratories in South San Francisco and San Diego, California and Austin, Texas. It also offers customized biomarker testing and analytical services.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
21.58 USD
Average target price
31.67 USD
Spread / Average Target
+46.74%
Consensus
  1. Stock
  2. Equities
  3. Stock Veracyte, Inc. - Nasdaq